多家跨国药企在学术会议公布阿尔茨海默病药物研究数据。8月1日晚,礼来中国对外宣布,来自礼来的最新研究TRAILBLAZER-ALZ 2三期临床研究的长期扩展(LTE)结果显示,接受多奈单抗注射液(商品名:记能达)治疗后能够实现长达三年的认知功能延缓,并保持良好的安全性特征。该研究成果已在于多伦多举办的2025年阿尔茨海默病协会国际会议(AAIC)上发布,该会议是全球规模最大的、最具影响力的致力于...
Source Link多家跨国药企在学术会议公布阿尔茨海默病药物研究数据。8月1日晚,礼来中国对外宣布,来自礼来的最新研究TRAILBLAZER-ALZ 2三期临床研究的长期扩展(LTE)结果显示,接受多奈单抗注射液(商品名:记能达)治疗后能够实现长达三年的认知功能延缓,并保持良好的安全性特征。该研究成果已在于多伦多举办的2025年阿尔茨海默病协会国际会议(AAIC)上发布,该会议是全球规模最大的、最具影响力的致力于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.